

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Not for submission under 37 CFR 1.99)	Application Number		10524963	
	Filing Date		2005-02-18	
	First Named Inventor	David Tonge		
	Art Unit	1614		
	Examiner Name	Royds, Leslie A		
Attorney Docket Number		100815-1P US		

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S. PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20030092757	A1	2003-05-15	Singh et al	

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1	1 424 080	EP	A1	2004-06-02	Takeda Chemical Industries, Ltd.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button.

Add

NON-PATENT LITERATURE DOCUMENTS			Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LAR/ (05/14/2009)

/Leslie A. Royds/ (05/14/2009)

Receipt date: 05/08/2006

Application Number	10524963	10524963 - GAU: 1614
Filing Date	2005-02-18	
First Named Inventor	David Tonge	
Art Unit	1614	
Examiner Name	Royds, Leslie A	
Attorney Docket Number	100815-1P US	

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Not for submission under 37 CFR 1.99)

1	LAURA ROSANO et al; ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances cytotoxicity of paclitaxel in human ovarian carcinoma in vitro and in vivo; AACR, Anaheim/Orange County, CA, April 16-20, 2005	<input type="checkbox"/>
2	CURTIS N et al; ZD4054 specifically inhibits endothelin A receptor-mediated anti-apoptotic effects, but not endothelin B receptor-mediated pro-apoptotic effects; AACR-NCI-EORTC, Geneva, Switzerland, 28 September-01 October, 2004	<input type="checkbox"/>
3	GLENN LIU et al; Tolerability profile of ZD4054 is consistent with the effects of endothelin A receptor-specific antagonism; ASCO Annual Meeting, Orlando, Florida, May 13-17, 2005	<input type="checkbox"/>
4	MORRIS C et al; ZD4054: specificity for endothelin A receptor following single-dose administration in healthy volunteers; AACR-NCI-EORTC, Geneva, Switzerland, 28 September-01 October, 2004	<input type="checkbox"/>
5	DREICER R et al; ZD4054 specifically inhibits endothelin A receptor-mediated effects but not endothelin B receptor-mediated effects; ASCO Prostate Cancer Symposium, Orlando, Florida, 17-19 February, 2005	<input type="checkbox"/>
6	MARTIN TODD et al; Metabolite Factories: Use of microbial systems to generate metabolites of an endothelin receptor antagonist; Biotrans 2005, Delft, The Netherlands, July 3-July 8, 2005	<input type="checkbox"/>
7	MORRIS et al; Specific inhibition of the endothelin A receptor with ZD4054: clinical and preclinical evidence; British Journal of Cancer (2005) 92, 2148-2152	<input type="checkbox"/>
8	MORRIS MICHAEL J ET AL : Clinical approaches to osseous metastases in prostate cancer. The Oncologist, 2003, 161-173, vol. 8, no. 2	<input type="checkbox"/>
9	CURTIS N. et al; ZD4054 Specifically Inhibits Endothelin A Receptor-Mediated Anti-Apoptotic Effects, But Not Endothelin B receptor-mediated pro-apoptotic effects; AACR-NCI-EORTC, Geneva, Switzerland, 28 September - 01 October, 2004	<input type="checkbox"/>
10	MORRIS C et al; ZD4054: specificity for endothelin A receptor following single-dose administration in healthy volunteers; AACR-NCI-EORTC, Geneva, Switzerland, 28 September-01 October, 2004	<input type="checkbox"/>
11	CURTIS et al; ZD4054 blocks ET-1-stimulated phosphorylation of p44/42 mitogen-activated protein kinase and proliferation of osteoblast cells; AACR, Anaheim/Orange County, CA, April 16-20, 2005	<input type="checkbox"/>

Receipt date: 05/08/2006

Application Number	10524963	10524963 - GAU: 1614
Filing Date	2005-02-18	
First Named Inventor	David Tonge	
Art Unit	1614	
Examiner Name	Royds, Leslie A	
Attorney Docket Number	100815-1P US	

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Not for submission under 37 CFR 1.99)

12	MORRIS et al; ZD4054 reduces endothelin-1-induced forearm vasoconstriction in healthy male volunteers; AACR, Anaheim/Orange County, CA, April 16-20, 2005	<input type="checkbox"/>
13	LAURA ROSANO et al; Combined targeting of the endothelin receptor and the epidermal growth factor receptor in ovarian cancer shows enhanced antiproliferative effects; AACR 2006, April 1 - 5, 2006, Washington, DC	<input type="checkbox"/>
14	J O CURWEN et al; ZD4054 : a specific endothelin A receptor antagonist with potential utility in prostate cancer and metastatic bone disease" EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 38, November 2002 (2002-11), page S102, XP004403782	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature	/Leslie A. Royds/ (05/14/2009)	Date Considered	
--------------------	--------------------------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LAR/ (05/14/2009)